Advertisement
Screener

NEUMORA THERAPEUTICS, INC. (NMRA) Graph

NMRA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $29.28M; Operating expenses $42.19M; Income tax $0.00; Net income -$43.08M.
  • 2026-03-31: Research and development $38.60M; Operating expenses $52.86M; Income tax $30.00K; Net income -$53.46M.
  • 2025-12-31: Research and development $44.67M*; Operating expenses $58.48M*; Income tax $0.00*; Net income $414.41M*.
  • 2025-09-30: Research and development $40.52M; Operating expenses $57.70M; Income tax $0.00; Net income -$56.76M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$29.28M$42.19M$0.00-$43.08M
2026-03-31$38.60M$52.86M$30.00K-$53.46M
2025-12-31$44.67M*$58.48M*$0.00*$414.41M*
2025-09-30$40.52M$57.70M$0.00-$56.76M
2025-06-30$38.72M$54.04M$25.00K-$52.73M
2025-03-31$52.15M$70.94M$105.00K-$67.99M
2024-09-30$60.63M$76.65M$53.00K-$72.55M
2024-06-30$48.63M$63.82M$125.00K-$58.70M
2024-03-31$45.76M$60.07M(m)-$53.72M
2023-09-30$41.60M$56.86M(m)-$53.03M
2023-06-30$32.77M$42.06M(m)-$38.54M
2023-03-31$29.48M$39.17M(m)-$35.63M
2022-09-30$22.55M$30.60M(m)-$29.34M
2022-06-30(m)(m)(m)-$30.37M
2022-03-31(m)(m)(m)-$43.04M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$67.88M$95.05M$30.00K-$96.54M
2025-06-30$90.88M$124.98M$130.00K-$120.72M
2024-06-30$94.39M$123.90M$125.00K-$112.42M
2023-06-30$62.25M$81.23M(m)-$74.17M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$131.40M$182.68M$130.00K-$177.48M
2024-09-30$155.01M$200.54M$178.00K-$184.97M
2023-09-30$103.86M$138.09M(m)-$127.19M
2022-09-30$68.23M$105.15M(m)-$102.76M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$176.06M$241.16M$130.00K$236.93M
2024-12-31$200.93M$263.46M$178.00K$243.79M
2023-12-31$142.72M$252.10M$268.00K-$235.93M
2022-12-31$91.75M$135.87M(m)-$130.90M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22